Eli Lilly’s Verzenio™ (Abemaciclib) receives FDA approval for certain advanced breast cancers

Last week the Food and Drug Administration (FDA) announced the approval of Eli Lilly’s breast cancer drug: Verzenio™ (Abemaciclib). This drug is a type of therapy called a CDK (cyclin-dependent kinase) inhibitor. Its approval is based on the results of two clinical trials, and we are proud to say Althian participated in one of them. Months ago, Eli Lilly announced the molecule was going to be evaluated as breakthrough therapy because of its very good results when the trials were being conducted.

In one trial, Abemaciclib was given to women with hormone receptor positive, HER2-negative advanced breast cancer in combination with Faslodex (or placebo with Faslodex). The other trial used Abemaciclib as the only treatment. The results were very good, since it showed a greater progression-free survival in women who received Abemaciclib in their treatment compared to the other arms.

Althian is proud to be participating in this kind of trials where we can clearly see how patients receive breakthrough therapies. We see every day how they can have another chance and hope and that is the most satisfying feeling. Now, seeing that one of the drugs we have experience working with is being approved, fills us with contentment.

Contact us for more information about the other drugs we have experience working with and how we can help you conduct your clinical trial.